QQQ   431.06 (-1.65%)
AAPL   172.69 (-2.19%)
MSFT   413.64 (-1.96%)
META   500.23 (-2.28%)
GOOGL   154.86 (-1.82%)
AMZN   183.62 (-1.35%)
TSLA   161.48 (-5.59%)
NVDA   860.01 (-2.48%)
AMD   160.32 (-1.81%)
NIO   3.89 (-5.35%)
BABA   70.62 (-0.94%)
T   16.24 (-0.43%)
F   12.23 (-3.01%)
MU   121.37 (-0.94%)
GE   153.70 (-0.60%)
CGC   6.98 (-10.51%)
DIS   112.95 (-0.93%)
AMC   2.47 (-6.79%)
PFE   25.91 (+0.19%)
PYPL   63.51 (-1.67%)
XOM   119.68 (-0.57%)
QQQ   431.06 (-1.65%)
AAPL   172.69 (-2.19%)
MSFT   413.64 (-1.96%)
META   500.23 (-2.28%)
GOOGL   154.86 (-1.82%)
AMZN   183.62 (-1.35%)
TSLA   161.48 (-5.59%)
NVDA   860.01 (-2.48%)
AMD   160.32 (-1.81%)
NIO   3.89 (-5.35%)
BABA   70.62 (-0.94%)
T   16.24 (-0.43%)
F   12.23 (-3.01%)
MU   121.37 (-0.94%)
GE   153.70 (-0.60%)
CGC   6.98 (-10.51%)
DIS   112.95 (-0.93%)
AMC   2.47 (-6.79%)
PFE   25.91 (+0.19%)
PYPL   63.51 (-1.67%)
XOM   119.68 (-0.57%)
QQQ   431.06 (-1.65%)
AAPL   172.69 (-2.19%)
MSFT   413.64 (-1.96%)
META   500.23 (-2.28%)
GOOGL   154.86 (-1.82%)
AMZN   183.62 (-1.35%)
TSLA   161.48 (-5.59%)
NVDA   860.01 (-2.48%)
AMD   160.32 (-1.81%)
NIO   3.89 (-5.35%)
BABA   70.62 (-0.94%)
T   16.24 (-0.43%)
F   12.23 (-3.01%)
MU   121.37 (-0.94%)
GE   153.70 (-0.60%)
CGC   6.98 (-10.51%)
DIS   112.95 (-0.93%)
AMC   2.47 (-6.79%)
PFE   25.91 (+0.19%)
PYPL   63.51 (-1.67%)
XOM   119.68 (-0.57%)
QQQ   431.06 (-1.65%)
AAPL   172.69 (-2.19%)
MSFT   413.64 (-1.96%)
META   500.23 (-2.28%)
GOOGL   154.86 (-1.82%)
AMZN   183.62 (-1.35%)
TSLA   161.48 (-5.59%)
NVDA   860.01 (-2.48%)
AMD   160.32 (-1.81%)
NIO   3.89 (-5.35%)
BABA   70.62 (-0.94%)
T   16.24 (-0.43%)
F   12.23 (-3.01%)
MU   121.37 (-0.94%)
GE   153.70 (-0.60%)
CGC   6.98 (-10.51%)
DIS   112.95 (-0.93%)
AMC   2.47 (-6.79%)
PFE   25.91 (+0.19%)
PYPL   63.51 (-1.67%)
XOM   119.68 (-0.57%)
NASDAQ:SMTI

Sanara MedTech (SMTI) Stock Price, News & Analysis

$32.25
-1.27 (-3.79%)
(As of 04:28 PM ET)
Today's Range
$32.05
$33.47
50-Day Range
$32.95
$40.20
52-Week Range
$26.06
$49.87
Volume
9,076 shs
Average Volume
13,377 shs
Market Capitalization
$278.09 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$44.00

Sanara MedTech MarketRank™ Stock Analysis

Analyst Rating
Buy
3.00 Rating Score
Upside/​Downside
36.4% Upside
$44.00 Price Target
Short Interest
Bearish
4.13% of Float Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
0.94mentions of Sanara MedTech in the last 14 days
Based on 2 Articles This Week
Insider Trading
N/A
Proj. Earnings Growth
N/A

Overall MarketRank

New Rank-Based ScoringMarketRank is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

1.80 out of 5 stars

Medical Sector

654th out of 928 stocks

Surgical Appliances & Supplies Industry

15th out of 18 stocks

SMTI stock logo

About Sanara MedTech Stock (NASDAQ:SMTI)

Sanara MedTech Inc. develops, markets, and distributes wound and skin care products to physicians, hospitals, clinics, and post-acute care settings in the United States. It also offers CellerateRX Surgical Activated Collagen powder and gel that are used in a range of surgical specialties to help promote patient healing; Biako¯s Antimicrobial Skin and Wound Cleanser, a patented product that disrupts extracellular polymeric substances to eradicate mature biofilm microbes; Biako¯s Antimicrobial Wound Gel, an antimicrobial hydrogel wound dressing helps against planktonic microbes, as well as immature and mature biofilms; and Biako¯s Antimicrobial Skin and Wound Irrigation Solution. The company provides HYCOL Hydrolyzed Collagen Powder and Gel, a medical hydrolysate of Type I bovine collagen for the management of full and partial thickness wounds, including pressure ulcers, venous and arterial leg ulcers, and diabetic foot ulcers. In addition, it develops FORTIFY TRG, a freeze-dried, multi-layer small intestinal submucosa extracellular matrix sheet; FORTIFY FLOWABLE extracellular matrix, an advanced wound care device; and VIM Amnion Matrix, a homologous wound covering product. Sanara MedTech Inc. was incorporated in 2001 and is based in Fort Worth, Texas.

SMTI Stock Price History

SMTI Stock News Headlines

Sanara Medtech Inc (SMTI)
Forget Nvidia, buy this A.I. Stock Now
Forget Nvidia, Microsoft or Google. Our tech expert and venture capitalist Luke Lango believes this is Elon Musk’s favorite A.I. stock. Why? Because this company is supplying Elon Musk with a key piece of advanced tech for his new A.I. venture.
Forget Nvidia, buy this A.I. Stock Now
Forget Nvidia, Microsoft or Google. Our tech expert and venture capitalist Luke Lango believes this is Elon Musk’s favorite A.I. stock. Why? Because this company is supplying Elon Musk with a key piece of advanced tech for his new A.I. venture.
Sanara MedTech's Earnings: A Preview
CGI Cellerate RX, LLC's Net Worth
Sanara MedTech Inks Exclusive License Agreement With Tufts University
Sanara MedTech Inc. Announces Third Quarter 2023 Results
Sanara MedTech Inc SMTI
See More Headlines
Receive SMTI Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Sanara MedTech and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
11/12/2021
Today
4/15/2024
Next Earnings (Estimated)
5/20/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Surgical appliances & supplies
Sub-Industry
N/A
Current Symbol
NASDAQ:SMTI
Fax
N/A
Employees
101
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$44.00
High Stock Price Target
$44.00
Low Stock Price Target
$44.00
Potential Upside/Downside
+31.3%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
1 Analysts

Profitability

Net Income
$-4,300,000.00
Pretax Margin
-6.83%

Debt

Sales & Book Value

Annual Sales
$64.99 million
Book Value
$5.22 per share

Miscellaneous

Free Float
3,863,000
Market Cap
$288.94 million
Optionable
Not Optionable
Beta
1.57
Beginner's Guide to Pot Stock Investing Cover

Click the link below and we'll send you MarketBeat's guide to pot stock investing and which pot companies show the most promise.

Get This Free Report

Key Executives

  • Mr. Ronald T. Nixon (Age 68)
    Executive Chairman
  • Mr. Zachary B. FlemingMr. Zachary B. Fleming (Age 49)
    Chief Executive Officer
    Comp: $593.64k
  • Mr. Michael D. McNeil (Age 59)
    CFO & Corporate Secretary
    Comp: $438.68k
  • Dr. Christopher A. Morrison FACHM (Age 54)
    FAPWCA, FCCWS, M.D., President of Telehealth Services
    Comp: $156k
  • Mr. Callon Nichols
    Vice President of Corporate Operations
  • Mr. Bill Fitzgerald
    Chief Compliance Officer
  • Ms. Tricia Matteson
    Vice President of Marketing
  • Dr. Rebecca Erin Mcmahon (Age 39)
    President of Research & Development
  • Mr. Seth Yon
    President of Commercial

SMTI Stock Analysis - Frequently Asked Questions

Should I buy or sell Sanara MedTech stock right now?

1 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Sanara MedTech in the last twelve months. There are currently 1 buy rating for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" SMTI shares.
View SMTI analyst ratings
or view top-rated stocks.

What is Sanara MedTech's stock price target for 2024?

1 brokers have issued 1 year target prices for Sanara MedTech's stock. Their SMTI share price targets range from $44.00 to $44.00. On average, they expect the company's share price to reach $44.00 in the next twelve months. This suggests a possible upside of 36.4% from the stock's current price.
View analysts price targets for SMTI
or view top-rated stocks among Wall Street analysts.

How have SMTI shares performed in 2024?

Sanara MedTech's stock was trading at $41.10 at the beginning of 2024. Since then, SMTI shares have decreased by 21.5% and is now trading at $32.25.
View the best growth stocks for 2024 here
.

When is Sanara MedTech's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Monday, May 20th 2024.
View our SMTI earnings forecast
.

How were Sanara MedTech's earnings last quarter?

Sanara MedTech Inc. (NASDAQ:SMTI) released its quarterly earnings results on Friday, November, 12th. The company reported ($0.27) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.18) by $0.09. The firm earned $5.82 million during the quarter. Sanara MedTech had a negative net margin of 6.62% and a negative trailing twelve-month return on equity of 11.12%. During the same period in the previous year, the business earned ($0.18) EPS.

What guidance has Sanara MedTech issued on next quarter's earnings?

Sanara MedTech updated its fourth quarter 2023 earnings guidance on Thursday, February, 22nd. The company provided earnings per share guidance of for the period. The company issued revenue guidance of $17.7 million-$17.7 million, compared to the consensus revenue estimate of $16.5 million.

What other stocks do shareholders of Sanara MedTech own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Sanara MedTech investors own include Lakeland Industries (LAKE), Ovintiv (OVV), SIG (SHI), Zynerba Pharmaceuticals (ZYNE), AbbVie (ABBV), American Airlines Group (AAL), Abbott Laboratories (ABT), AC Immune (ACIU) and Applied Genetic Technologies (AGTC).

How do I buy shares of Sanara MedTech?

Shares of SMTI stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:SMTI) was last updated on 4/15/2024 by MarketBeat.com Staff

From Our Partners